Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07468292

GARDE : GC7 (N1-guanyl-1,7 Diaminoheptane) cARDiac arrEst

Cardiac arrest (CA) with return of spontaneous circulation is associated with high mortality, exceeding 90% in out-of-hospital settings and approaching 50% in in-hospital settings. Despite management of the underlying cause of CA, patients often die from post-anoxic brain injury or from ischemia-reperfusion injury occurring after reperfusion and reoxygenation, which increases oxidative stress and leads to multi-organ failure. To date, no effective therapeutic strategy has been established in humans to limit these ischemia-reperfusion injuries. GC7 (N1-guanyl-1,7 diaminoheptane) has demonstrated a strong protective potential against ischemia reperfusion injury in rodent and porcine models, including myocardial infarction, stroke, and renal transplantation. These protective effects are attributed to the pleiotropic action of GC7 which renders cells and tissues energetically less dependent on oxygen, and reduces oxidative stress which play a major role in ischemia reperfusion injury. Degree of blood acidification and immune dysregulation may also represent parameters that GC7 could potentially influence. Although no adverse effects have been reported in these experimental models, GC7 has not yet been studied in human. Our study therefore aims to demonstrate the protective effect of GC7 on blood cells in patients after CA by evaluating oxidative stress levels, blood acidification and inflammatory profile.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Cardiac arrest as the primary reason for hospital admission
  • Admission < 48 hours
  • Age ≥ 18 years
  • Affiliated with a social security system

Exclusion criteria

  • Limitation or withdrawal of life-sustaining therapies prior to study screening
  • Prior cardio-vascular ischemic event (> 24h) before cardiac arrest
  • Patient deprived of liberty

Treatment and study plan

GC7 exposure

Other

24-hour exposure of patient 's blood to GC7 molecule

No GC7 exposure

Other

No exposure of blood to GC7 molecule

Primary outcomes

  1. Blood oxidative stress levels

    Time frame: at 24 hours after blood exposure to GC7

Secondary outcomes

  1. Blood acidification

    Time frame: 24 hours after blood exposure to GC7

  2. Blood inflammatory profile

    Time frame: 24 hours after blood exposure to GC7

Study contacts

Contact information is provided by the study sponsor or research team.

DOMINIQUE DONZEAU

CONTACT

[email protected]

+33492034560

Denis DOYEN, MD

CONTACT

[email protected]

+33492033615

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nice

Other

Registry information

Official study title

Impact of GC7 (N1-guanyl-1,7 Diaminoheptane) on Oxidative Stress in Patients Who Have Experienced a Resuscitated Cardiorespiratory Arrest

Acronym: GARDE

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Mar 12, 2026
Registry last updated
Mar 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.